Imprimis NJOF, LLC Initiates Class III Recall for Sub-Potent Ophthalmic Solution
Imprimis NJOF, LLC has initiated a Class III recall for 2,890 vials of its Tropicamide-Proparacaine-Phenylephrine-Ketorolac Sterile Ophthalmic Solution due to sub-potency identified during stability testing. This voluntary, firm-initiated action impacts nationwide distribution in the USA, requiring immediate review of inventory and supply chain implications for affected pharmaceutical procurement and regulatory teams.
FDA Mandates Class III Recall for Sub-Potent Imprimis NJOF Ophthalmic Solution
ChemLifeIntel reports that Imprimis NJOF, LLC has initiated a Class III recall, designated D-0536-2025, for 2,890 vials of its Tropicamide-Proparacaine-Phenylephrine-Ketorolac, Sterile Ophthalmic Solution. This multi-component ophthalmic product, identified by NDC 71384-733-05, was distributed nationwide across the USA. The critical issue identified was sub-potency, specifically subpotent assay results discovered during routine stability testing of lot 25MAR032, which carried an expiration date of July 16, 2025. For procurement directors and regulatory affairs heads, this means an immediate assessment of inventory is necessary to identify and quarantine affected stock. The sub-potency of active pharmaceutical ingredients (APIs) directly impacts the therapeutic efficacy of the drug, posing risks to patient outcomes in ophthalmology. Supply chain VPs must recognize that while this is a Class III recall—indicating the least serious type where adverse health consequences are unlikely—any deviation from specified potency standards reflects a fundamental quality control failure. This event underscores the necessity for robust supplier qualification and continuous monitoring, particularly for complex compounded or specialized formulations like this ophthalmic solution. Business development executives should note that such quality lapses can erode market trust and necessitate strategic adjustments in product portfolio management.
Imprimis NJOF's Ledgewood Facility: Production and Quality Control Implications
The recalled Tropicamide-Proparacaine-Phenylephrine-Ketorolac ophthalmic solution originated from Imprimis NJOF, LLC's facility located at 1705 Route 46 Ste 6B, Ledgewood, NJ 07852-9720, within the United States. While specific details regarding the facility's overall production capacity, global API supply role, or key markets beyond nationwide USA distribution are not available from the provided data, this incident highlights critical vulnerabilities in pharmaceutical manufacturing quality systems. The detection of sub-potency through stability testing indicates a potential breakdown in formulation development, manufacturing process control, or analytical testing methodologies. For procurement directors, this means that reliance on a single source for specialized ophthalmic preparations, especially those with multiple active ingredients, carries inherent risks. Regulatory affairs heads must ensure that their internal quality audit programs are sufficiently rigorous to identify and mitigate similar risks with their own suppliers. This event serves as a reminder that even established facilities can experience quality excursions, necessitating continuous vigilance over supplier performance and product quality attributes throughout the shelf-life.
Supply Chain Exposure and Procurement Strategies for Ophthalmic Formulations
The nationwide distribution pattern of Imprimis NJOF, LLC's sub-potent ophthalmic solution means that healthcare providers, pharmacies, and distributors across the entire USA are potentially exposed to this recall. Given the multi-component nature of Tropicamide-Proparacaine-Phenylephrine-Ketorolac, this product likely serves niche applications in ophthalmology, potentially making immediate alternatives less readily available. Procurement directors must initiate rapid communication with their internal clinical and pharmacy teams to identify all locations that may have received lot 25MAR032. The commercial implications extend beyond direct financial losses from returned product; they include potential reputational damage, administrative costs associated with managing the recall, and the critical need to ensure uninterrupted patient care with alternative, compliant products. Supply chain VPs should leverage this event to re-evaluate their risk management frameworks for specialized pharmaceutical products, focusing on supplier diversity and the robustness of quality agreements. For business development executives, understanding the competitive landscape for such complex formulations becomes paramount, as quality issues can swiftly shift market share towards more reliable suppliers. This situation underscores the importance of having pre-qualified alternative sources for critical, multi-API drug products.
Post-Recall Actions and Regulatory Outlook for Imprimis NJOF
The recall of the Tropicamide-Proparacaine-Phenylephrine-Ketorolac Sterile Ophthalmic Solution by Imprimis NJOF, LLC was firm-initiated and has been classified as 'Completed' by the FDA. While the immediate action of removing the affected product (recall number D-0536-2025) from the market is concluded, the underlying issues that led to sub-potency during stability testing typically trigger a deeper internal investigation by the company. For regulatory affairs heads, this means that even though no specific FDA Warning Letter or 483 observation is detailed in this recall notice, the FDA will expect comprehensive corrective and preventive actions (CAPA) to address the root cause of the quality failure. The voluntary nature of the recall indicates the firm's proactive engagement, but it does not preclude future regulatory scrutiny, especially if systemic quality control deficiencies are identified. Supply chain VPs should anticipate that any supplier experiencing such a recall will be under increased internal and external pressure to demonstrate robust quality system improvements. Business development executives should consider how such events impact long-term supplier viability and market perception, influencing future partnership decisions and due diligence processes. The absence of historical regulatory actions in the provided data does not diminish the significance of this current quality lapse.